Despite newer targeted therapies, patients with primary refractory or relapsed (r/r) T-cell
lymphoma have a poor prognosis. The development of chimeric antigen receptor (CAR) T …

While cytokine release syndrome and immune effector cell‐associated neurotoxicity
syndrome are well‐recognized acute toxicities of chimeric antigen receptor (CAR) T cell …

Adoptive cell therapies engineered to express chimeric antigen receptors (CARs) or
transgenic T cell receptors (TCRs) to recognize and eliminate cancer cells have emerged as …

HHV-6B reactivation affects approximately half of all allogeneic hematopoietic cell transplant
(HCT) recipients. HHV-6B is the most frequent infectious cause of encephalitis following …

Although the approval of new drugs has improved the clinical outcome of multiple myeloma
(MM), it was widely regarded as incurable over the past decades. However, recent …

Impaired function of hematopoiesis after treatment with chimeric antigen T‐cells (CAR‐T) is
a frequent finding and can interest a wide range of patients, regardless of age and …

Hematologic toxicity frequently complicates chimeric antigen receptor (CAR) T-cell therapy,
resulting in significant morbidity and mortality. In an effort to standardize reporting, the …

Autoimmune diseases (ADs) are characterized by loss of immune tolerance, high chronicity,
with substantial morbidity and mortality, despite conventional immunosuppression (IS) or …

Chimeric antigen receptor (CAR) T cell therapies have dramatically improved treatment
outcomes for patients with relapsed or refractory B-cell acute lymphoblastic leukemia, large …

Chimeric antigen receptor (CAR) T-cell therapy is a promising immunotherapy based on
genetically engineered T cells derived from patients. The introduction of CAR T-cell therapy …